ANTI CANCER PHARMACEUTICAL PREPARATIONS

Brand Owner (click to sort) Address Description
AJOURNEE BRISTOL-MYERS SQUIBB COMPANY 430 E. 29th Street, 14th Floor New York NY 10016 Anti-cancer pharmaceutical preparations;
ANISINA Kazia Research Pty Ltd Level 24, 300 Barangaroo Avenue SYDNEY NSW 2000 Australia Anti-cancer pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer;Color is not claimed as a feature of the mark.;
BICARA Bicara Therapeutics Inc. 245 Main Street Cambridge MA 02142 anti-cancer pharmaceutical preparations;
CANTRIXIL canTx, Inc. CTech, United States Anti-cancer pharmaceutical preparations; Pharmaceutical preparations for the treatment of cancer; medical therapeutic agents for the treatment of cancer; medical therapeutic drugs for the treatment of cancer;
FRELAST BRISTOL-MYERS SQUIBB COMPANY 430 E. 29th Street, 14th Floor New York NY 10016 anti-cancer pharmaceutical preparations;
LUTRATE GP Pharm S.A. Polígono Industrial Els. Vinyets-Els Fogars, 2 Carretera C-244 Km Spain Anti-cancer pharmaceutical preparations; pharrmaceutical preparations for the treatment of cancer;Color is not claimed as a feature of the mark.;
LUTRATE GP Pharm S.A. Polígono Industrial Els. Vinyets-Els Fogars, 2 Carretera C-244 Km Spain Anti-cancer pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer;
NOVOGEN Kazia Research Pty Ltd Level 24, 300 Barangaroo Avenue SYDNEY NSW 2000 Australia Anti-cancer pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; compounds for treating cancer;Medical research in the field of cancer and degenerative disease treatments; and developing pharmaceuticals for the treatment of cancer and degenerative diseases;
NOVOGEN Novogen Research Pty Ltd 140 Wicks Rd NORTH RYDE NSW 2113 Australia Anti-cancer pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; compounds for treating cancer;Medical research in the field of cancer and degenerative disease treatments; and developing pharmaceuticals for the treatment of cancer and degenerative diseases;
ONAPON BRISTOL-MYERS SQUIBB COMPANY 430 E. 29th Street, 14th Floor New York NY 10016 anti-cancer pharmaceutical preparations;
ONQUEL BRISTOL-MYERS SQUIBB COMPANY 430 E. 29th Street, 14th Floor New York NY 10016 anti-cancer pharmaceutical preparations;
QUISTRA BRISTOL-MYERS SQUIBB COMPANY 430 E. 29th Street, 14th Floor New York NY 10016 anti-cancer pharmaceutical preparations;
RIBAGENE Ribapharm Inc. Legal Department 3300 Hyland Ave Costa Mesa CA 92626 Anti-cancer pharmaceutical preparations;
TAPOVA BRISTOL-MYERS SQUIBB COMPANY 430 E. 29th Street, 14th Floor New York NY 10016 anti-cancer pharmaceutical preparations;
TAPOVA BRISTOL-MYERS SQUIBB COMPANY 430 E. 29th Street, 14th Floor New York NY 10016 anti-cancer pharmaceutical preparations;
TRILEXIUM Kazia Research Pty Ltd Level 24, 300 Barangaroo Avenue SYDNEY NSW 2000 Australia Anti-cancer pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; medical therapeutic agents for the treatment of cancer; medical therapeutic drugs for the treatment of cancer;
UFT COMBO-PACK BRISTOL-MYERS SQUIBB COMPANY 430 E. 29th Street, 14th Floor New York NY 10016 anti-cancer pharmaceutical preparations;UFT COMBO PACK;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.